GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlycoMimetics Inc (FRA:GKO) » Definitions » Research & Development

GlycoMimetics (FRA:GKO) Research & Development : €19.11 Mil (TTM As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is GlycoMimetics Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. GlycoMimetics's Research & Development for the three months ended in Mar. 2024 was €5.54 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was €19.11 Mil.

GlycoMimetics Research & Development Historical Data

The historical data trend for GlycoMimetics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlycoMimetics Research & Development Chart

GlycoMimetics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 42.33 36.93 42.03 26.80 18.41

GlycoMimetics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.06 3.76 4.96 4.85 5.54

GlycoMimetics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €19.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlycoMimetics  (FRA:GKO) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

GlycoMimetics Research & Development Related Terms

Thank you for viewing the detailed overview of GlycoMimetics's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

GlycoMimetics (FRA:GKO) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlycoMimetics Inc (FRA:GKO) » Definitions » Research & Development
Comparable Companies
SGMT ACHV AAGH CMRX ATOS ARMP HRGN GTHX OMGA DMAC OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
GLYC:USA
Address
9708 Medical Center Drive, Rockville, MD, USA, 20850
Website
https://www.glycomimetics.com
GlycoMimetics Inc is a clinical stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it plays in inflammation, cancer, and infection.